دورية أكاديمية
Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use.
| العنوان: | Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use. |
|---|---|
| المؤلفون: | Fleseriu M; Departments of Medicine and Neurological Surgery, Pituitary Center, Oregon Health & Science University, Portland, OR, USA., Nachtigall LB; Neuroendocrine Clinical Center, Massachusetts General Hospital Neuroendocrine and Pituitary Center, Chestnut Hill, MA, USA., Samson SL; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Neurologic Surgery, Mayo Clinic, Jacksonville, FL, USA., Melmed S; Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. |
| المصدر: | Expert review of endocrinology & metabolism [Expert Rev Endocrinol Metab] 2024 Jul; Vol. 19 (4), pp. 367-375. Date of Electronic Publication: 2024 Jun 06. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278293 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8417 (Electronic) Linking ISSN: 17446651 NLM ISO Abbreviation: Expert Rev Endocrinol Metab Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2014- > : London : Taylor & Francis Original Publication: London, UK : Future Drugs Ltd., c2006- |
| مواضيع طبية MeSH: | Acromegaly*/drug therapy , Octreotide*/administration & dosage , Octreotide*/therapeutic use , Octreotide*/adverse effects , Antineoplastic Agents, Hormonal*/administration & dosage , Antineoplastic Agents, Hormonal*/therapeutic use , Antineoplastic Agents, Hormonal*/adverse effects , Quality of Life*, Humans ; Administration, Oral ; Capsules ; Adenoma/drug therapy ; Growth Hormone-Secreting Pituitary Adenoma/drug therapy ; Clinical Trials as Topic ; Treatment Outcome |
| مستخلص: | Introduction: Acromegaly is a rare endocrine disorder usually caused by a benign growth hormone‒secreting pituitary adenoma. Surgical adenoma resection is typically the first line of treatment, and medical therapy is used for patients with persistent disease following surgery, for adenoma recurrence, or for patients ineligible for, or declining, surgery. Approved somatostatin receptor ligands (SRLs) have been limited to injectable options, until recently. Oral octreotide capsules (OOC) are the first approved oral SRL for patients with acromegaly. Areas Covered: We review published reports and provide case study examples demonstrating practical considerations on the use of OOC. Using two hypothetical case scenarios, we discuss current treatment patterns, breakthrough symptoms and quality of life (QoL), efficacy of SRLs, OOC dose titration, evaluation of OOC treatment response, and incidence and management of adverse events. Expert Opinion: OOC are an option for patients with acromegaly including those who experience breakthrough symptoms, who have preference for oral therapies, or other reasons for declining injectable SRLs. OOC have been associated with improved patient-reported QoL measures compared with those reported for lanreotide and octreotide. Continued real-world experience will determine whether OOC, alone or in combination with other therapies, provides further advantages over current injectable acromegaly treatments. |
| فهرسة مساهمة: | Keywords: Acromegaly; HRQoL; OOC; case study; dose titration; oral octreotide capsules; pituitary adenoma; somatostatin receptor ligand |
| المشرفين على المادة: | RWM8CCW8GP (Octreotide) 0 (Antineoplastic Agents, Hormonal) 0 (Capsules) |
| تواريخ الأحداث: | Date Created: 20240606 Date Completed: 20240620 Latest Revision: 20240620 |
| رمز التحديث: | 20240620 |
| DOI: | 10.1080/17446651.2024.2363540 |
| PMID: | 38842362 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8417 |
|---|---|
| DOI: | 10.1080/17446651.2024.2363540 |